All In Biotech

Drug Trial Radar · NCT07927010

A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)

A Phase 2/3, Randomized, Double-Masked, Vehicle-Controlled, Dose-Ranging Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Mar 2029

Study completion Mar 2029

Sponsor

Lead sponsor
Mighty Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Approximately 300 subjects with eligible dry AMD will be randomized to one of three groups (low dose Bevemipretide, high dose Bevemipretide, or vehicle) to receive daily ophthalmic solution administration for 48 weeks.

Conditions

  • Dry AMD
  • Age-Related Macular Degeneration (AMD)

Interventions

  • 1 % BevemipretideDrug

    Low Dose 1% bevemipretide ophthalmic topical solution

  • 2% BevemipretideDrug

    High Dose 2% bevemipretide ophthalmic topical solution

  • VehicleOther

    Vehicle for this trial will be composed of sodium chloride and phosphate buffer, similar to excipients used to manufacture the active drug, but without the active drug substance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Change in Macular Area of Photoreceptor Loss through week 48Time frame: 48 Weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.